Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Premium Biopharma Specialist Cormorant Plans New $125 Million Blank-Check Venture Stephen Taub AustralianSuper CIO and Deputy CEO Mark Delaney to Retire in 2026 James Comtois II Communities on Alternative Investments Sponsored by Fidelity Investments